Palisade Bio, Inc. $PALI Shares Acquired by Orbimed Advisors LLC

Orbimed Advisors LLC lifted its holdings in Palisade Bio, Inc. (NASDAQ:PALI) by 24.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,333,000 shares of the company’s stock after buying an additional 461,580 shares during the period. Orbimed Advisors LLC’s holdings in Palisade Bio were worth $4,083,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Cetera Investment Advisers acquired a new stake in Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio in the 4th quarter worth approximately $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $28,000. Atom Investors LP acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $33,000. Finally, Barclays PLC purchased a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Oppenheimer assumed coverage on Palisade Bio in a report on Thursday. They issued an “outperform” rating and a $8.00 price target for the company. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a report on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Insider Activity at Palisade Bio

In related news, CEO John David Finley sold 146,798 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the transaction, the chief executive officer directly owned 217,555 shares in the company, valued at approximately $450,338.85. This represents a 40.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera bought 30,000 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were acquired at an average cost of $2.03 per share, with a total value of $60,900.00. Following the purchase, the director owned 416,904 shares of the company’s stock, valued at $846,315.12. The trade was a 7.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 125,000 shares of company stock worth $250,100. Insiders own 0.07% of the company’s stock.

Palisade Bio Price Performance

NASDAQ:PALI opened at $1.95 on Monday. The company’s 50-day moving average is $1.92 and its two-hundred day moving average is $1.89. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.86. The firm has a market capitalization of $338.48 million, a price-to-earnings ratio of -1.93 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities analysts anticipate that Palisade Bio, Inc. will post -0.24 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.